更新于：2024-12-27

Cefotaxime Sodium

头孢噻肟钠

更新于：2024-12-27

概要

概要

基本信息

药物类型

小分子化药

别名

(6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid、(6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid、(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid

+ [15]

靶点

PBPs

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Pfizer Australia Pty Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

四川省长征药业股份有限公司

+ [3]

非在研机构

SteriMax, Inc.

B. Braun Medical, Inc.

最高研发阶段批准上市

首次获批日期

(1980-01-01),

革兰氏阴性菌感染革兰氏阳性细菌感染莱姆病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C16H17N5NaO7S2

InChIKeyUWNYOXHAYFLGIE-JUZDKLSSSA-N

CAS号64485-93-4

关联

项与头孢噻肟钠相关的临床试验

NCT06712641 / Not yet recruiting临床4期IIT

Aminoglycosides in Early Sepsis (AGES): a Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams As Empirical Treatment in Patients with Suspected Sepsis

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance.
In patients with suspected community acquired sepsis, we hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, we hypothesize the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, we hypothesize the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

开始日期2025-06-01

申办/合作机构

Akershus Universitetssykehus HF

[+1]

NCT06406114 / Not yet recruiting临床2期IIT

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

开始日期2025-02-01

申办/合作机构

The General Hospital Corp.

[+1]

CTRI/2024/08/073105 / Not yet recruitingN/AIIT

A COMPARATIVE STUDY OF CEFOTAXIME VS MEROPENEM AS EMPIRICAL TREATMENT IN SPONTANEOUS BACTERIAL PERITONITIS - SBP CURE

开始日期2024-09-19

申办/合作机构-

100 项与头孢噻肟钠相关的临床结果

登录后查看更多信息

100 项与头孢噻肟钠相关的转化医学

登录后查看更多信息

100 项与头孢噻肟钠相关的专利（医药）

登录后查看更多信息

13,065

项与头孢噻肟钠相关的文献（医药）

2025-02-01·MICROBIAL PATHOGENESIS

Evaluation of multi-drug resistance, virulence factors, and antimicrobial resistance genes of non-typhoidal Salmonella isolated from ruminants as a potential human health threat in Razavi Khorasan, northeastern Iran

Article

作者: Badouei, Mahdi Askari ; Hashemi Tabar, Gholamreza ; Zavari, Ali

Non-typhoidal Salmonella (NTS) is a significant foodborne pathogen that poses a threat to human health by causing infections and potentially acquiring antibiotic resistance. We evaluated thirty-five Salmonella serovars previously isolated from cattle, sheep, goats, and their retail meat in Razavi Khorasan Province, Iran. The isolates were confirmed with Salmonella polyvalent antiserum. Furthermore, PCR was used to identify the Salmonella Enteritidis, Salmonella Typhimurium, and the host-adapted serovars Salmonella Dublin and Salmonella Abortusovis. Additionally, the antimicrobial susceptibility of the serovars was evaluated using the disk diffusion method. Subsequently, the occurrence of antimicrobial resistance genes and virulence factors was evaluated using the PCR technique. Molecular typing revealed that 20 % of the isolates were S. Typhimurium, 11.4 % were S. Dublin, 8.6 % were S. Enteritidis, 5.7 % were S. Abortusovis, and 54.3 % (19 isolates) were classified as non-typed serovars. Salmonella isolates showed high susceptibility to ciprofloxacin (91.4 %), colistin (88.6 %), gentamicin (88.6 %), and cefotaxime (85.7 %) while exhibiting high resistance to others such as ampicillin (88.6 %), streptomycin (74.3 %), and tetracycline (51.4 %). The most prevalent resistance genes in non-typhoidal Salmonella (NTS) are bla_TEM (91.4 %), sul1 (65.7 %), and aadA (54.3 %). Additionally, twenty-five isolates (71.4 %) showed multi-drug resistance profiles. The most frequent virulence genes are stn (100 %), iroN (100 %), and pefA (42.9 %). The current study has revealed that Salmonella serovars isolated from sheep and goats, like those from cattle, exhibit multi-drug resistance and harbor antimicrobial resistance genes. Additionally, they possess diverse virulence factors that can threaten human health by spreading diseases and developing drug resistance, leading to antibiotic treatment failure.

2025-02-01·Infectious disorders drug targets

A Case Report of Salmonella enterica Meningitis in an Infant: A Rare Entity not to Forget

Article

作者: Tzanoudaki, Marianna ; Farmaki, Evangelia ; Gkentzi, Despoina ; Palyvou, Maria ; Syrogiannopoulos, George ; Angeli, Evangelia ; Varvarigou, Anastasia ; Dimitriou, Gabriel

Introduction::

Salmonellae are gram-negative, facultatively anaerobic Enterobacteri-aceae consisting of two species, Salmonella enterica and Salmonella bongori. Invasive diseases, such as meningitis, result in hospitalization, short and long-term complications, and high mortality rates.

Case Presentation::

A 4-month-old baby girl was admitted to a district hospital because of diarrhea and fever. WBC count, urinalysis, urine cultures, and stool cultures were normal. She was treated with intravenous cefuroxime for 5 days. She was discharged on oral cefprozil for 5 days. After the end of therapy, she was admitted again to the same hospital with fever, diarrhea, vomits, and irri-tability. Cerebrospinal fluid examination revealed pleocytosis, while S. enterica was isolated. Em-pirical therapy with ceftriaxone, amikacin, and dexamethasone was started. Because of intracranial hypertension signs, she was transferred to the pediatric intensive care unit of our tertiary hospital. Therapy continued with intravenous ceftriaxone. Brain MRI revealed subarachnoid space dilata-tion. Increased head circumference and pulsating bregmatic fontanel led to a new cerebral MRI, in which ventricular dilatation and extraparenchymal subdural collection were noted. Ceftriaxone was changed to cefotaxime and ciprofloxacin was added. She remained clinically well; her brain MRI, a week later, showed marked improvement, and the course of intravenous antibiotics for 5 weeks was completed. Her baseline immunodeficiency screening tests were normal and repeat MRI two months post-treatment cessation did not reveal the previous abnormalities.

Conclusion::

Invasive Salmonella diseases, such as meningitis, are very uncommon in industrial countries nowadays, and the optimal management is yet not well established. Late onset of com-plications from Salmonella meningitis warrants more thorough neurodevelopmental follow-ups.

2025-02-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Immunostimulatory effects of rhamnogalacturonan-I fraction purified from Glycyrrhiza glabra roots on cyclophosphamide-induced immunosuppressed mice

Article

作者: Shin, Kwang-Soon ; Park, Ju-Hyeon ; Kim, Ki Hyun ; Jung, Uk Sun ; Son, Seung-U

The present study aimed to investigate the immunostimulatory activities of polysaccharides purified from Glycyrrhiza glabra root. First, five polysaccharide fractions were separated from G. glabra through hot water extraction, ethanol precipitation, enzymatic hydrolysis, and size exclusion chromatography. Among them, G. glabra polysaccharide-enzyme (GRPE)-I showed the potent stimulation effect on cytokine secretion from peritoneal macrophage. Moreover, glycosidic linkage analysis indicated the GRPE-I mainly comprised 4-linked galacturonic acid, 2,4-linked rhamnose, 3,6-linked galactose, 4,6-linked galactose, and 5-linked arabinosef, which are characteristics of rhamnogalacturonan (RG)-I type polysaccharide. Immunostimulatory effect of GRPE-I in vivo was investigated in cyclophosphamide (CTX)-induced immunosuppressed mice model. As a results, the pre-administration of GRPE-I demonstrated significant benefits against reducing body weight and damaging lymphoid tissue. Additionally, GRPE-I affected regulation of various immunocytes population such as macrophage, natural killer cell, CD4⁺ T cell, CD8⁺ T cell. Serum and spleen tissue analysis results indicate improvement about immunoglobulin and cytokine levels by GRPE-I. These results are strongly correlated with the activation of the mitogen-activated protein kinase and nuclear factor-kappa B pathways. Furthermore, CTX-induced short chain fatty acid impairment was reversed by GRPE-I. In conclusion, GRPE-I, which is a RG-I type polysaccharide isolated from G. glabra, exhibits significant potential as a novel immunomodulator.

184

项与头孢噻肟钠相关的新闻（医药）

2024-12-25

·echemi

Investigation of Three Drugs for Invoice Fraud Affects Stock Market Fluctuations

On December 20, China’s National Healthcare Security Administration (NHSA) issued an official letter to provincial and regional healthcare bureaus, requiring an investigation into ginkgo leaf extract injection, cefotaxime sodium injection, and hydrolyzed protein oral solution to determine whether these products are involved in invoice fraud schemes similar to recent cases in the pharmaceutical industry. The investigation aims to clarify the actual net prices of these products. The NHSA's letter highlighted that, according to a report by Economic Information Daily, public security authorities cracked two pharmaceutical invoice fraud cases in 2022 and 2024. These investigations revealed a dual-pricing system for pharmaceuticals, including a "list price" and a "net price." Manufacturers sold medicines to distributors at the list price, and distributors then sold them to medical institutions. After transactions, the price difference between the list price and net price was refunded to the distributors. This price gap, disguised through fraudulent invoices, was then withdrawn as profits or used for commercial bribery, artificially inflating drug prices from the source. For instance, the report detailed that the net price of ginkgo leaf extract injection was CNY 8.5 per unit, while its list price reached CNY 25.28 per unit, generating a commission of CNY 4 per unit for doctors. Similarly, cefotaxime sodium injection's net price was CNY 6.5 per unit, and its list price was CNY 16.5 per unit, with a doctor commission of CNY 2.5 per unit. Commissions commonly accounted for over 20% of the price gap between the list and net prices. The mentioned drugs are linked to several listed companies, leading to significant stock price fluctuations upon the market opening on Monday. Among these, Sci-Tech Innovation Board-listed Yekang Pharmaceutical saw its stock price plunge over 18% intraday, closing down more than 14% due to its flagship ginkgo leaf extract injection being named. According to Yekang’s IPO prospectus, this product's hospital sales volume and revenue grew significantly from 2017 to 2019. Companies such as Kangyuan Pharmaceutical and Yibai Pharmaceutical, also involved in ginkgo products, saw their stock prices decline by 2.09% and 4.61%, respectively. Cefotaxime sodium injection also triggered major declines in the shares of multiple companies. As the second-largest product in cefalosporins with a national hospital market sales value exceeding CNY 3.5 billion in 2023, the drug’s inclusion in the investigation sent Lingkang Pharmaceutical's stock price to a daily limit down, while Luoxin Pharmaceutical fell 6.12% and Zhendong Pharmaceutical dropped 5.41%. Notably, cefotaxime sodium injection remains outside China’s national centralized procurement program despite widespread use of other cefalosporins within the program.

IPO生物类似药

2024-12-23

·GlobeNewswire-Health Care

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The new funding supports the progression of Basilea’s novel antibiotic candidate BAL2420 (LptA inhibitor) towards the start of first-in-human clinical studies, which is expected mid-2026. Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: "We are very pleased by CARB-X’s continued support for the development of this promising first-in-class drug candidate. LptA inhibitors have the potential to address an unmet medical need in the hospital-based treatment of severe infections, caused by Gram-negative bacteria. We look forward to working with CARB-X to bring BAL2420 to patients." BAL2420 belongs to one of the very few novel classes of antibiotics in development. It is targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy.1 Enterobacteriaceae have been highlighted by the World Health Organization (WHO) as priority pathogens, against which new antibiotics are urgently needed.2 Basilea has acquired the LptA antibiotics program from Spexis AG in early 2024. In April this year, Basilea announced that it was awarded an initial CARB-X grant of up to USD 0.9 million to support early preclinical activities. The successful completion of these activities resulted in the nomination of BAL2420 as a drug candidate and also led to a final milestone payment from Basilea to Spexis. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About CARB-X CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. https://carb-x.org/ | X (formerly Twitter) @CARB_X About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerlandPhone+41 61 606 1102E-mailmedia_relations@basilea.cominvestor_relations@basilea.com This ad hoc announcement release can be downloaded from www.basilea.com. References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683https://www-who-int.libproxy1.nus.edu.sg/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: December 22, 2024) Attachment Press release (PDF)

合格传染病产品

2024-12-17

·医脉通

病例实战丨胃肠道大量出血的罕见罪魁祸首：阿米巴虫

在临床实践中，胃肠道出血是一个常见的急症，其原因多种多样，从常见的胃溃疡到更为罕见的感染性疾病。本文将介绍一例罕见的胃肠道出血病例，患者是一位26岁的男性，因持续的大便带血和晕厥症状入院治疗。通过一系列详细的辅助检查和内镜检查，最终在组织活检中发现了阿米巴滋养体，确诊为阿米巴感染。本病例不仅揭示了阿米巴感染在非流行区的罕见病例，也强调了在诊断胃肠道出血时考虑阿米巴感染的重要性，尤其是对于有旅行史的患者。 01 患者概述 1999-2023 病例概述：患者性别男，年龄26岁（截至2024年）。主诉：患者因“大便呈暗红色血迹持续1日，伴有1次晕厥”而入院治疗。现病史：患者近半年内曾两次前往东南亚某国（具体细节未详述），随后出现大便带血、出汗、心悸及低血压症状，并伴有1次晕厥。患者在外院接受治疗（具体治疗措施未详述）后未见明显改善，为进一步诊治收治入院。鉴于患者的旅行史，初步怀疑其可能患有某种传染病，故采取相应治疗措施。 02 辅助检查 1999-2023 实验室检查：凝血功能及肿瘤标志物正常；粪便培养和涂片试验，EBV IgM(-), CMV DNA（-）；T-SPOT结核试验阴性。腹部增强CT：回肠末端和盲肠明显增厚和强化（图A）。胃镜检查显示胃炎。结肠镜检查（图B1）：回肠末端和盲肠有糜烂和浅溃疡。7天后行小肠内镜检查：回盲瓣对侧新增2.0*2.0 cm凸起病灶，表面溃疡，周围粘膜水肿（图B2）。病理活检：黏膜炎性细胞浸润，活检组织中发现了阿米巴滋养体（图C）。图A：末端回肠和盲肠增厚和增强 03 诊疗经过 1999-2023 患者病理检查结果显示存在炎性细胞浸润现象，随后采用头孢噻肟进行抗炎治疗，并配合益生菌以促进肠道功能的恢复。在出院三个月的随访中，先前观察到的结肠凸起病灶已消失不见，结肠镜检查（见图B3）仅在盲肠和升结肠区域发现少量散在的小溃疡。图B：B1.回肠末端和盲肠的糜烂和浅溃疡；B2.回盲瓣对侧2.0*2.0 cm凸起病灶；B3.假性肿瘤样病变消失，仅在盲肠和升结肠出现散在的小溃疡图C：活检组织中的阿米巴滋养体 04 病例讨论 1999-2023 患者的症状和影像学表现起初并不典型，阿米巴感染在临床上也较为少见，尤其是在非流行区，因此容易被忽视。患者半年内有前往东南亚的旅行史，这为诊断提供了重要线索，阿米巴感染主要通过摄入被污染的食物和水传播，旅行史和生活习惯是重要的风险因素。患者经过辅助检查发现，腹部增强CT显示回肠末端和盲肠显著增厚和强化，这些表现与阿米巴感染引起的炎症和组织破坏有关，内镜检查发现的糜烂和溃疡进一步支持了这一诊断，组织活检中发现阿米巴滋养体是确诊的关键。阿米巴感染的治疗通常包括抗阿米巴药物，如甲硝唑和二氯尼特，但在本病例中，抗生素和益生菌的综合治疗也取得了良好的效果。 · 总结 · 本病例报道了一例罕见的由阿米巴引起的严重消化道出血。通过详细的病史采集、影像学检查、内镜检查和组织病理学检查，最终确诊并成功治疗。该病例提醒临床医生在遇到消化道出血患者时，应考虑到阿米巴感染的可能性，特别是有相关旅行史的患者，及时诊断和治疗可以显著改善患者的预后。参考文献： A Rare Culprit of Massive Gastrointestinal Bleeding: Amoeba.The American Journal of Gastroenterology ():10.14309/ajg.0000000000003181, October 31, 2024. | DOI: 10.14309/ 医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

100 项与头孢噻肟钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00919	头孢噻肟钠	J01DD01	DB00493

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
感染	中国	Sanofi SA	2006-05-29
淋病	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
耳感染	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
脑膜炎	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
鼻腔感染	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
咽炎	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
术后感染	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
呼吸道感染	澳大利亚	Pfizer Australia Pty Ltd.	2001-08-22
细菌感染	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1981-09-19
细菌感染	日本	Sanofi KK	1981-09-19
菌血症	美国	SteriMax, Inc.	1981-03-11
骨和关节感染	美国	SteriMax, Inc.	1981-03-11
中枢神经系统感染	美国	SteriMax, Inc.	1981-03-11
妇科感染	美国	SteriMax, Inc.	1981-03-11
腹腔感染	美国	SteriMax, Inc.	1981-03-11
下呼吸道感染	美国	SteriMax, Inc.	1981-03-11
脓毒症	美国	SteriMax, Inc.	1981-03-11
皮肤和皮肤结构感染	美国	SteriMax, Inc.	1981-03-11
泌尿道感染	美国	SteriMax, Inc.	1981-03-11
革兰氏阴性菌感染	-	Pharma Holdings US, Ltd	1980-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Am J Gastroenterol	N/A	自发性细菌性腹膜炎一线	261	Cefotaxime	齋壓製繭淵顧鏇齋淵夢(艱積鑰顧夢簾網願選窪) = 餘觸膚醖鏇淵簾衊選壓襯鹽齋窪壓獵壓構壓遞 (夢築願醖廠餘夢艱衊築 )	-	2023-01-02
Pubmed \| Am J Gastroenterol	N/A	自发性细菌性腹膜炎一线	261	Ceftriaxone	齋壓製繭淵顧鏇齋淵夢(艱積鑰顧夢簾網願選窪) = 築壓鬱積齋壓襯選繭構襯鹽齋窪壓獵壓構壓遞 (夢築願醖廠餘夢艱衊築 )	-	2023-01-02
WCLC2022	N/A	小细胞肺癌	59	Sequential ACOCEV	範選鬱衊衊築餘積願淵(膚顧壓膚鹹憲衊築膚餘) = 獵壓衊觸壓選鏇築廠鹽鹹製糧醖築糧淵襯壓齋 (網製鹽鏇顧蓋壓觸膚鏇 ) 更多	-	2022-08-06
ISN WCN2020	N/A	急性肾小管间质性肾炎 \| 肾小球肾炎	-	Cefotaxime	願醖積構鏇獵淵鏇網製(築憲顧構範觸艱觸願鹹) = acute granulomatous interstitial nephritis and crescentic pauci-immune glomerulonephritis associated to Cefotaxime 糧襯夢願繭襯蓋憲襯鏇 (顧艱積範襯積襯積蓋願 )	积极	2020-03-01
NCT00187655 (CTgov)	临床1期	-	24	Cefotaxime	遞襯獵糧選艱衊餘築糧(範鹹鏇衊艱衊齋齋窪襯) = 製遞窪淵鹹構糧鏇淵糧餘簾遞壓選壓觸繭顧鹹 (鏇齋願壓鹹選艱壓製鏇, 醖簾觸鏇糧繭醖鏇構願 ~ 選齋蓋憲蓋鏇齋積簾艱) 更多	-	2014-05-12
EULAR2009	N/A	系统性红斑狼疮	73	Low-dose IV CTX regimen	襯範獵壓醖壓願餘顧鏇(選選網膚鏇範餘製壓衊) = 簾艱選憲膚鹹鹽餘廠醖範淵鬱鏇夢積襯膚遞醖 (鹽醖蓋糧繭糧觸簾膚觸 ) 更多	-	2009-06-10
EULAR2009	N/A	系统性红斑狼疮	73	High-dose IV CTX regimen	襯範獵壓醖壓願餘顧鏇(選選網膚鏇範餘製壓衊) = 齋構鏇衊築範顧餘繭範範淵鬱鏇夢積襯膚遞醖 (鹽醖蓋糧繭糧觸簾膚觸 ) 更多	-	2009-06-10